Looks like the head of the diaDexus joint
diagnostics company venture, W. Gerber, is leaving for
another CEO position. A possible indication that things
aren't going well at that company that Incyte had formed
with Smith Kline.
Either that or maybe he left
because his stock options are under water.
INCY generally doesn't need any reason to rally
or fall in price...it is one of the strangest stocks
I have seen and follow.
I am worried about
the insider filings. One can debate how true of an
insider they are but they regardless know the inner
workings better than us common folks.
In looking at the list on Yahoo of insiders, few
of these folks are employees, and none are players.
Some are investers, the biggest blocks are the ex-CFO,
a KP related fund, and ex the ex-Synteni founder
(long since gone from Incyte) and his trust and related
Look closely - definitly not management or important
INCY should consider buying out HYSQ. HYSQ seems
to have some hope of winning their lawsuit against
AFFX (see recent releases) and having HYSQ patents
might strengthen INCY negotiating position vs. AFFX in
its lawsuit. Besides HYSQ only has a $50 million or
so market cap. Also, HYSQ is relatively close by, so
the integration issues might be relatively less.